Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

El estudio PRECISION-T2D: estudio nutricional de precisión para la diabetes tipo 2

24 de septiembre de 2026 actualizado por: Westlake University

Food plays a crucial role in determining blood glucose levels, especially in people with type 2 diabetes. Precision nutrition, which involves individually tailored dietary interventions, can be a powerful tool in managing blood glucose levels in people with type 2 diabetes. Previous studies found that changes in gut microbiota resulted from the dietary intervention, such as plant-based diet, might subsequently lead to different glycemic responses, and then different health outcomes.

In this study, the investigators will characterize the blood glucose dynamics and gut microbiota of individuals with type 2 diabetes. They aim to assess the influence of plant-based diet on gut microbiota; they will also investigate the influence of gut microbiota on glycemic responses. Additionally, a series of individual N-of-1 trails will be integrated to compare the effects of a white bread breakfast and a whole wheat bread breakfast on glucose metabolism at the individual level.

Descripción general del estudio

Descripción detallada

Choice of design: The study is a two-arm intervention study integrated with N-of-1 design.

Study population: Patients with type 2 diabetes.

Screening Assessment: Prospective participants will be selected based on the pre-defined inclusion and exclusion criteria. Recruitment will be done over the phone and via the social media.

Study duration: Each participant will take part in the study for a period of up to 1 month at baseline and have follow-up visits every 1-2 years.

Dietary intervention:

The PRECISION-T2D is a dietary intervention study. Upon admission, patients will be randomly assigned to two groups: plant-based diet and conventional diabetic diet. Throughout the hospitalization, all participants (n=200) will be given standardized meals. A dietitian will design the diet for both plant-based and conventional diabetic diet groups following 2023 Chinese Diabetes Society guidelines. Both diets comprised approximately 50-65% of energy from carbohydrates, 20-30% of energy from fat, 15-20% from protein. The plant-based diet had higher fiber content (25-30g) compared to the conventional diabetic diet (15-20g). Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any leftover food. All participants will be asked to track their meals, snacks and drinks with instructions on how to record their daily dietary information. Participants will also be advised not to modify their exercise habits during the course of the study. Upon discharge, Participants in the plant-based diet arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. Participants in the conventional diabetic diet arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. Individual N-of-1 trial design will be employed to all participants during day one to day twelve to compare the difference of postprandial glucose response to white bread or whole wheat bread. These two standard breakfasts will appear in pseudo-random order. During the participants' first baseline visit day, they will be asked to complete a baseline questionnaire to collect information on their lifestyle, dietary habits, history of medications, sleep quality and appetite. Anthropometric measurements, ultrasonography evaluation, and laboratory tests will be taken using standard protocols. Participants will then be asked to wear a continuous glucose monitor (CGM) for 14-day blood glucose monitoring, which will be done by a nurse. On day 14, participants will be asked to come in for a clinical visit where they will receive their CGM report and provide blood, saliva, urine and stool samples. On day 30, participants will be asked to come in for another clinical visit where they will provide blood, saliva, urine and stool samples.

Tipo de estudio

Intervencionista

Inscripción (Actual)

144

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310058
        • Hangzhou Third People's Hospital
      • Hangzhou, Zhejiang, Porcelana, 310030
        • Westlake University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

35 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Diagnosed with type 2 diabetes;
  • Living in Hangzhou for at least five years;
  • Have the willingness or ability to complete the intervention and sample collection

Exclusion Criteria:

  • Mental and physical disability;
  • Already is a vegetarian;
  • Cancer and serious complications from type 2 diabetes, such as renal failure;
  • Using insulin for more than 5 years;
  • Unstable medical/medication status;
  • Current alcohol or drug abuse;
  • Taking antibiotics in the last three months

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Plant-based diet

Participants in this arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. All participants are instructed not to modify their exercise habits during the intervention period.

After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.

Otros nombres:
  • Desayuno A

After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.

Otros nombres:
  • Desayuno B

After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.

Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.

Experimental: Conventional diabetic diet

Participants in this arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. All participants are instructed not to modify their exercise habits during the intervention period.

After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.

Otros nombres:
  • Desayuno A

After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.

Otros nombres:
  • Desayuno B

Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.

Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Continuous glucose monitoring-derived mean blood glucose
Periodo de tiempo: 2 weeks

Real-time glucose profiles will be recorded using continuous glucose monitoring. Average of all glucose measurements during the up to 14 days CGM wear will be calculated in mmol/L.

2 weeks
Continuous glucose monitoring-derived time-in-range
Periodo de tiempo: 2 weeks

Real-time glucose profiles will be recorded using continuous glucose monitoring. Percentage of glucose measurements that wear in the range of 3.9-10.0 mmol/L during the up to 14 days CGM will be calculated.

2 weeks
Continuous glucose monitoring-derived coefficient of variation
Periodo de tiempo: two weeks

Continuous glucose monitoring-derived time-in-range Real-time glucose profiles will be recorded using continuous glucose monitoring. Coefficient of variation was defined as standard deviation divided by mean glucose and multiplied by 100, during the up to 14 days wear.

two weeks
Changes in gut microbiome profile
Periodo de tiempo: Day 1, 15 and 31

Shotgun metagenomic sequencing will be performed in stool samples.

Day 1, 15 and 31

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Changes in fasting blood glucose
Periodo de tiempo: Day 1, 15 and 31

Fasting glucose will be examined in mmol/L.

Day 1, 15 and 31
Changes in fasting blood C-peptide
Periodo de tiempo: Day 1, 15 and 31

Fasting blood C-peptide will be examined in μg/L.

Day 1, 15 and 31
Changes in fasting blood HbA1c
Periodo de tiempo: Day 1, 15 and 31

Fasting blood HbA1c will be examined in %.

Day 1, 15 and 31
Changes in lipid metabolism
Periodo de tiempo: Day 1, 15 and 31

Triglyceride, cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol will be examined in mmol/L.

Day 1, 15 and 31

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Ju-Sheng Zheng, PhD, Westlake University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

17 de julio de 2023

Finalización primaria (Actual)

4 de enero de 2026

Finalización del estudio (Actual)

4 de enero de 2026

Fechas de registro del estudio

Enviado por primera vez

23 de marzo de 2023

Primero enviado que cumplió con los criterios de control de calidad

30 de mayo de 2023

Publicado por primera vez (Actual)

2 de junio de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir